Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Robinhood Markets, Inc. (HOOD) Price & Performance

Abeona Therapeutics IncTrade
Robinhood Markets, Inc.Trade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Robinhood Markets, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Robinhood Markets, Inc. trades at $94.3 (market cap $84.86B). The key difference: Robinhood Markets, Inc. is far larger — about 201.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals.

ABEOHOOD
Market Cap
$421.19M$84.86B
Sector
HealthTechnology
52-Week High
$7.45$152.46
52-Week Low
$4.17$65.16
Enterprise Value
$276.10M$91.40B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Robinhood Markets, Inc.

Robinhood Markets (HOOD) trades at $94.40, down 0.13% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust Q2 2026 results with revenue growth of 32% and earnings beating expectations, driven by diversification beyond crypto into event contracts and international expansion. Valuation metrics remain elevated with P/E of 41.76 and P/S of 17.6, reflecting premium pricing for growth prospects.

The outlook remains positive with analyst consensus pointing to significant upside (target $123.46), though near-term technical weakness and competitive pressures in the UK crypto expansion present risks. Revenue diversification and strong cash flow generation support long-term growth, but investors should monitor execution on international expansion and margin sustainability amid high valuations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Robinhood Markets, Inc.

Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.

Read more on HOOD